The future: aligning regulatory and health technology assessments outcomes
This article was originally published in SRA
The aims of the different stakeholders are too diverse for there to be true convergence of regulatory and HTA outcomes in the pharmaceutical arena. But much can still be done to improve on the current situation, says Johan Strömquist.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."